Fox Run Management’s Tenaya Therapeutics TNYA Stock Holding History

Fox Run Management’s Portfolio TNYA Stock Details TNYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-15,251	Closed	-$79.8K	–	1083
2024 Q1	$79.8K	Buy	+15,251	New	+$73K	0.02%	712

Other funds holding TNYA

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Fox Run Management's TNYA Position: Q2 2024 in Review

Fox Run Management sold out of Tenaya Therapeutics (TNYA) in Q2 2024, closing a stake of 15,251 shares — an estimated $79.8K sold.

Fox Run Management first reported a position in TNYA in Q1 2024 and held it in 1 quarter. The position peaked at $79.8K in Q1 2024. 96 funds tracked by Wall St. Rank hold TNYA as of Q2 2024.

Fox Run Management reported no remaining Tenaya Therapeutics position as of Q2 2024 after selling out during the quarter.
Fox Run Management sold 15,251 Tenaya Therapeutics shares in Q2 2024, an estimated $79.8K.
Fox Run Management first reported a position in Tenaya Therapeutics in Q1 2024 and held it in 1 quarter.
Fox Run Management's Tenaya Therapeutics position peaked at $79.8K in Q1 2024.
96 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2024.

Based on Fox Run Management's 13F filing for Q2 2024, filed 13 Aug 2024.